GlassScriptPhysician profile
Caroline Drusano Chell
NPI 1194571505
$1,189.88
in general payments reported to CMS, 2019-2025
22 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $719 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $115.32 | 2024-2025 | Farxiga, Airsupra |
| Amgen INC. | $107.87 | 2024 | Repatha, Otezla, Krystexxa |
| Novo Nordisk INC | $95.65 | 2025 | Rybelsus, Ozempic |
| Lundbeck LLC | $94.22 | 2024-2025 | Rexulti |
| Abbvie INC. | $86.72 | 2024-2025 | |
| Lilly USA, LLC | $75.60 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Grifols USA, LLC | $64.88 | 2024-2025 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $60.31 | 2024 | Zemaira |
| Pfizer INC. | $60.22 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $47.31 | 2024-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.07 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $43.30 | 2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $42.92 | 2024-2025 | Ingrezza |
| Baxter Healthcare | $33.80 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.13 | 2025 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.90 | 2025 | Veozah |
| Almatica Pharma LLC | $32.36 | 2024 | Loreev Xr, Teriparatide |
| Janssen Pharmaceuticals, INC | $30.63 | 2024 | Spravato |
| Merck Sharp & Dohme LLC | $29.27 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sumitomo Pharma America, INC. | $28.71 | 2024 | Gemtesa |
| Esperion Therapeutics, INC. | $14.99 | 2024 | Nexletol |
| Globus Medical, INC. | $13.70 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Chell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.